For HBeAg (+) hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In the investigators study, patients were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
For HBeAg positive hepatitis B patients who have been treated by entecavir for 48 weeks but without HBeAg loss, switching to peg-interferon may increase the response rate. In our study, patients without HBeAg loss to 48 weeks entecavir treatment were divided into two groups. In Group A, patients continued entecavir for another 72 weeks. In Group B, patients switched to peg-interferon-2a monotherapy for 48 weeks, then followed up 24 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
entecavir 0.5mg per day
Peginterferon alfa-2a 180ug per week
The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
HBeAg sericonversion rate
Time frame: 72 weeks
HBeAg loss rate
Time frame: 72 weeks
HBeAg quantification dynamic change
Time frame: 72 weeks
HBsAg loss rate
Time frame: 72 weeks
HBsAg seroconversion rate
Time frame: 72 weeks
HBsAg quantification dynamic change
Time frame: 72 weeks
ALT normalization rate
Time frame: 72 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.